Abstract
Objective: Development of inhibitors in hemophilia A and B comprise major challengechallenges for patients, hematologists, and health provider systems. It has been recommended by the World Federation of Hemophilia (WFH) to check itthis every 3-4 months. Owing to the lower frequency of hemophilia B regard toin comparison with hemophilia A, this survey was done to control inhibitors in hemophilia B hasand look at whether or not they have been neglected or not?.
Method: To end this, a comprehensive review was done using 6 international and local medical search engines on published contributions about inhibitors in hemophilia A and B in Iran.
Results: AmongFrom 699 titles, 12 relevant papers were selected. The inhibitors in hemophilia A has been paidwere in 6 papers, while only one paper has been aboutcovered the inhibitors in hemophilia B. There were five common papers on hemophilia A and B. The comparison between studiedthe patients studied showed that 3020 patients with hemophilia A and 314 patients with hemophilia B have been reported.
Conclusion: Consistent with the lower frequency of hemophilia B and also the lower development of inhibitors in hemophilia B thancompared to hemophilia A, it was concluded that hemophilia B has not been neglected in Iran. It seems that each country wouldshould be doing a similar survey to convinceshow that inhibitors in hemophilia B have not been neglected.

Keywords: hemophilia A, hemophilia B, factor VIII inhibitors, factor IX inhibitors

Impact Statement:
DevelopmentThe development of inhibitors in patients with hemophilia is regarded as the mostbiggest challenge for both patients and hematologists. Managing and controlling of bleeding events in hemophilia with inhibitors are more complicated and more expensive. Owing to the frequency of hemophilia B isand about 1/3 of hemophilia A and on the other hand incidenceincidences of developing inhibitors in hemophilia B isbeing less in comparison to hemophilia A. There, there is a risk that detection of inhibitors through doing a Bethesda or Nijmegen assay for patients with hemophilia B may be neglected. This mini-review tries to pay attention to inhibitors in hemophilia B.